In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method

Taj-Aldeen, Saad J.; Salah, Husam; Al‐Hatmi, Abdullah M. S.; Hamed, Manal; Theelen, Bart; Diepeningen, A.D. van; Boekhout, Teun; Lass‐Flörl, Cornelia

doi:10.1016/j.diagmicrobio.2016.05.006

Cited by 47 publications

(56 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5). There is biological plausibility to this observation inasmuch as Fusarium species are associated with high amphotericin B MICs (27). Amphotericin B had no significant effect on the relative abundance of other taxa over time.…”

mentioning

confidence: 88%

Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia

Robinson

Peterson

Sahasrabhojane

et al. 2020

mSphere

View full text Add to dashboard Cite

Although the term "microbiome" refers to all microorganisms, the majority of microbiome studies focus on the bacteriome. Here, we characterize the oral mycobiome, including mycobiome-bacteriome interactions, in the setting of remissioninduction chemotherapy (RIC) for acute myeloid leukemia (AML). Oral samples (n ϭ 299) were prospectively collected twice weekly from 39 AML patients during RIC until neutrophil recovery. Illumina MiSeq 16S rRNA gene (V4) and internal transcribed spacer 2 (ITS2) sequencing were used to determine bacterial and fungal diversity and community composition. Intrakingdom and interkingdom network connectivity at baseline (T1) and at midpoint (T3) and a later time point (T6) were assessed via SPIEC-EASI (sparse inverse covariance estimation for ecological association inference). In this exploratory study, mycobiome ␣-diversity was not significantly associated with antibiotic or antifungal receipt. However, postchemotherapy mycobiome ␣-diversity was lower in subjects receiving high-intensity chemotherapy. Additionally, greater decreases in Malassezia levels were seen over time among patients on high-intensity RIC compared to low-intensity RIC (P ϭ 0.003). A significantly higher relative abundance of Candida was found among patients who had infection (P ϭ 0.008), while a significantly higher relative abundance of Fusarium was found among patients who did not get an infection (P ϭ 0.03). Analyses of intrakingdom and interkingdom relationships at T1, T3, and T6 indicated that interkingdom connectivity increased over the course of IC as bacterial ␣-diversity diminished. In (to our knowledge) the first longitudinal mycobiome study performed during AML RIC, we found that mycobiome-bacteriome interactions are highly dynamic. Our study data suggest that inclusion of mycobiome analysis in the design of microbiome studies may be necessary to optimally understand the ecological and functional role of microbial communities in clinical outcomes. IMPORTANCE This report highlights the importance of longitudinal, parallel characterization of oral fungi and bacteria in order to better elucidate the dynamic changes in microbial community structure and interkingdom functional interactions during the injury of chemotherapy and antibiotic exposure as well as the clinical consequences of these interrelated alterations.

show abstract

mentioning

confidence: 88%

Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia

Robinson

Peterson

Sahasrabhojane

et al. 2020

mSphere

View full text Add to dashboard Cite

show abstract

“…Keratitis and onychomycosis are local infections that are also related to this fungus, sometimes associated with previous trauma and possible dissemination related to the above‐mentioned patient‘s immune status. Therefore, for optimal treatment, surgical debridement of the infected tissue is performed ,…”

Section: Introductionmentioning

confidence: 99%

Allylic Selenocyanates as New Agents to Combat Fusarium Species Involved with Human Infections

et al. 2017

View full text Add to dashboard Cite

Fusarium is an emerging opportunistic fungal pathogen that causes local or systemic infections. The successful use of a therapeutic drug or combination antifungal therapies against Fusarium spp. are compromised because reports of multidrug resistance are currently frequent. Thus, the development of new antifungal capable of combating multidrug‐resistant Fusarium strains becomes necessary. This study presents the synthesis of seven new allylic selenocyanates and their screening against Fusarium spp. Minimum inhibitory concentrations (MICs) of these compounds ranged from 4 to 64 μg mL−1, with the mechanism of action being related to fungal cell membrane disruption. Specific structural changes, such as widespread thinning along the hyphae, were observed by scanning electron microscopy. The effect of selenocyanates on cell viability and genotoxicity are concentration dependent, however they did not cause mutagenicity in human cells. Five selenocyanates were identified as nonirritant by the ex‐vivo HET‐CAM (Hen′s Egg Test‐Chorioallantoic Membrane) method. Allylic selenocyanates represents a promising alternative in the treatment and prevention of fusariosis.

show abstract

“…Intrinsic resistance to azoles and high in vitro MIC values to polyenes and the echinocandins have been noted, although some studies reported successful clinical outcomes with these agents (8)(9)(10)(11)(12)(13)(14). Currently, European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and European Confederation of Medical Mycology (ECMM) joint guidelines and most published studies suggest that early therapy with amphotericin B and voriconazole in conjunction with surgical debridement and reversal of immunosuppression is the treatment of choice for disseminated fusariosis (13)(14)(15). However, survival rates are low in these patient populations (ϳ30% or less), particularly among patients with constant immunosuppression (13)(14)(15)(16)(17).…”

mentioning

confidence: 99%

“…Currently, European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and European Confederation of Medical Mycology (ECMM) joint guidelines and most published studies suggest that early therapy with amphotericin B and voriconazole in conjunction with surgical debridement and reversal of immunosuppression is the treatment of choice for disseminated fusariosis (13)(14)(15). However, survival rates are low in these patient populations (ϳ30% or less), particularly among patients with constant immunosuppression (13)(14)(15)(16)(17). In keratitis cases, topical natamycin is used along with voriconazole as the mainstay of Fusarium treatment (18).…”

mentioning

confidence: 99%

Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species

Abastabar

Al‐Hatmi

Moghaddam

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

A collection of clinical ( = 47) and environmental ( = 79) isolates were tested against 10 antifungal drugs, including 2 novel imidazoles. Luliconazole and lanoconazole demonstrated very low geometric mean MIC values of 0.005 and 0.013 μg/ml, respectively, compared with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B, and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due to species.

show abstract

In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method

Cited by 47 publications

References 35 publications

Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia

Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia

Allylic Selenocyanates as New Agents to Combat Fusarium Species Involved with Human Infections

Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species

Contact Info

Product

Resources

About